GlobeNewswire·Mar 10, 2026, 8:59 AM ET

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Clearmind Medicine Inc. announced the publication of an international PCT patent application for a novel combination therapy integrating MEAI with Palmitoylethanolamide (PEA).
The MEAI-PEA combination targets weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD) as a non-hallucinogenic neuroplastogen treatment.
PEA is supplied through a collaboration between Clearmind Medicine and NeuroThera Labs Inc., a subsidiary of SciSparc Ltd.
The therapy aims to address obesity, which affects over 890 million adults, and MASLD, which impacts approximately 30% of the global adult population.
The company positions this treatment as a potentially safer, easier, & more cost-effective alternative to GLP-1 agonists.
The global weight loss drugs market was valued at approximately $37 billion in 2025 & is forecasted to reach $226 billion by 2035.
Clearmind Medicine currently holds 19 patent families including 31 granted patents & intends to expand its intellectual property portfolio.
Shares of Clearmind Medicine trade on Nasdaq under the symbol "CMND".